We previously reported that the precursor form of nerve growth factor (pro-NGF) and not mature NGF is liberated in the CNS in an activity-dependent manner, and that its maturation and degradation occur in the extracellular space by the coordinated action of proteases. Here, we present evidence of diminished conversion of pro-NGF to its mature form and of greater NGF degradation in Alzheimer disease (AD) brain samples compared with controls. These alterations of the NGF metabolic pathway likely resulted in the increased pro-NGF levels. The pro-NGF was largely in a peroxynitrited form in the AD samples. Intrahippocampal injection of amyloid-A oligomers provoked similar upregulation of pro-NGF in naive rats that was accompanied by evidence of microglial activation (CD40), increased levels of inducible nitric oxide synthase, and increased activity of the NGF-degrading enzyme matrix metalloproteinase 9. The elevated inducible nitric oxide synthase provoked the generation of biologically inactive, peroxynitrite-modified pro-NGF in amyloid-A oligomerYinjected rats. These parameters were corrected by minocycline treatment. Minocycline also diminished altered matrix metalloproteinase 9, inducible nitric oxide synthase, and microglial activation (CD40); improved cognitive behavior; and normalized pro-NGF levels in a transgenic mouse AD model. The effects of amyloid-A amyloid CNS burden on NGF metabolism may explain the paradoxical upregulation of pro-NGF in AD accompanied by atrophy of forebrain cholinergic neurons.
INTRODUCTION
Alzheimer disease (AD) is an age-related neurodegenerative disorder characterized by progressive loss of memory and deterioration of higher cognitive functions. The remarkable vulnerability of the cholinergic system to the amyloid-A (AA) pathology that characterizes AD is not understood. The profound loss and atrophy of basal forebrain cholinergic neurons (BFCNs) that innervate the hippocampus and the cerebral cortex contribute to the dementia-related cognitive decline and remain a main target for therapeutic intervention in AD (1) .
Maintenance of the biochemical-morphological phenotype of BFCNs in adult animals is dependent on the supply of endogenous nerve growth factor (NGF) (2, 3) . Furthermore, the steady state numbers of cholinergic synapses in the cerebral cortex are regulated by minute amounts of endogenous NGF (4) . It would, therefore, be expected that in AD, there would be a loss of biologically active NGF. There is, however, no evidence for diminished NGF synthesis in AD (5, 6) . Paradoxically, upregulation in the levels of NGF precursor protein (pro-NGF) has been well documented (7, 8) . Moreover, alterations in NGF and its high-affinity receptor (TrkA) have been observed in early and late stages of AD, and increased levels of pro-NGF (7, 9) and loss of cortical TrkA (10) have been reported in subjects with mild cognitive impairment as well as in AD. The mechanism by which AA accumulation in AD leads to upregulation of pro-NGF with a concomitant atrophy of NGF-dependent BFCNs remains unresolved.
Recently, we gathered experimental evidence in rodents for the involvement of an extracellular protease cascade in the conversion of pro-NGF released in an activity-dependent manner to NGF and for the degradation/inactivation of NGF caused by the coordinated release and activation of matrix metalloproteinase 9 (MMP-9) (Fig. 1) . We provided evidence that this mechanism is also operative in vivo because application of inhibitors of converting enzymes to the CNS led to the upregulation of brain pro-NGF levels, whereas inhibition of the degrading protease led to accumulation of mature NGF (11) . We speculate that the pathway responsible for the maturation and degradation of NGF might explain the paradox of elevated pro-NGF and atrophy of NGF-dependent BFCNs in AD. Therefore, we hypothesize that AA accumulation in AD might provoke alterations of NGF maturation/degradation mechanisms, thereby reducing the levels of mature NGF (11) ; this would explain the remarkable vulnerability of FCNs in AD.
Here, we investigated the status of this postulated NGF-processing pathway in AD by analyzing the components of the NGF protease cascade in human cortical tissue samples from AD and nondemented age-matched controls. We further determined whether alterations observed in AD brains also occur in a transgenic mouse model of the AD-like amyloid pathology and whether they can be experimentally replicated by the intrahippocampal injection of soluble AA oligomers in naive rats. In both experimental models, dysregulation of NGF metabolism was accompanied by early evidence of inflammation and peroxynitration of NGF; these abnormalities were corrected by treatment with minocycline. 
MATERIALS AND METHODS

Human Brain Material
Experimental Animals
Four-month-old Fischer 344 rats were used to observe the effects of AA oligomers in the NGF maturation/degradation processing pathway. Two-month-old transgenic (McGillThy1-APP transgenic mouse model) and nontransgenic littermate mice were also used. Efforts were made to minimize the number of animals used and their suffering. All procedures were approved by the Animal Care Committee of McGill University and followed the guidelines of the Canadian Council on Animal Care.
Surgical Procedures and Hippocampal Injections
Fischer 344 rats were divided into 3 experimental groups: the first group (n = 5) was injected bilaterally into the hippocampus (following coordinates from the bregma: anteroposterior, j0.45 mm; lateral, T0.35 mm; vertical, 0.35 mm) with 1 Kg of AA oligomers, the second group (n = 5) FIGURE 1. Schematic representation of the nerve growth factor (NGF) metabolic pathway. Upon stimulation, stored precursor form of NGF (pro-NGF), plasminogen, tissue plasminogen activator (tPA) and propeptide matrix metalloproteinase 9 (pro-MMP-9) are released from neurons into the extracellular space. Released tPA induces the conversion of plasminogen to plasmin. The generated plasmin converts pro-NGF into mature NGF and pro-MMP-9 into active MMP-9. Mature NGF then interacts with its cognate receptors (TrkA and p75 neurotrophin receptor) or be degraded by activated MMP-9. L  920  6  NCI  115  230  244  30  89  F  R  889  3  NCI  65  214  235  27  82  F  R  950  8  NCI  90  265  93  38  78  M  R  1,112  9  NCI  75  137  180  32  91  M  L  872  10  NCI  80  245  231  26  77  F  L  920  5  NCI  95  204  224  22  68  M  R  1,200  9  NCI  75  188  99  34  ( 255  7  AD  200  210  156  122  85  F  R  1,020  5  AD  170  132  63  90  88  M  L  1,460  4  AD  135  95  81  75  67  F  L  950  6  AD  154  108  54  128  74  M  L  1,350  12  AD  210  167  170  69  71  F  R  880  4  AD  122  215  58  91  88  F  R  1,050  9  AD  100  98  77 received bilaterally 1 Kg of the reverse control peptide 42-1 (American Peptides, Sunnyvale, CA); the third group (n = 5) was treated 24 hours before the bilateral AA oligomer injections (1 Kg) with minocycline (intraperitoneally, 50 mg/kg) (12) and daily with the same dose of minocycline (intraperitoneally) for 72 hours and then killed. Each animal was anesthetized, placed in the stereotaxic apparatus (David Kopf Instruments, Tujunga, CA), and received bilaterally a single injection of 3-KL solution containing AA oligomers or the 42-1 reverse control peptide diluted in phosphate-buffered artificial cerebrospinal fluid (150 mmol/L NaCl, 1.8 mmol/L CaCl 2 , 1.2 mmol/L MgSO 4 , 2 mmol/L K 2 HPO 4 , 10 mmol/L glucose, and 0.001% rat serum, pH 7.4), using a Hamilton syringe pump (flow rate, 0.25 KL/minute). The needle was left in place for 5 minutes before the injection was started; the solution was injected slowly for a period of 12 minutes. The needle was then left in place for approximately 2 to 5 minutes and retracted slowly to prevent backwash up the needle tract. After injection, the skull was swabbed, and the skin overlying the skull was closed with surgical stitches. Animals were kept alive for 72 hours and were then killed, and the hippocampus was removed and homogenized.
For intraparenchymal administration of native NGF versus peroxynitrite-modified NGF, the procedures were followed as described above, but animals (n = 5) were killed 2 hours after the injection. The doses administered (150 ng) diluted in artificial cerebrospinal fluid (final volume, 3 KL every 12 minutes) were previously shown to induce pronounced tyrosine phosphorylation of Trk-type proteins 2 hours after the injection (13) .
Minocycline Pellet Implantation
Mice were anesthetized with Equithesin (composition: 1.2 g pentobarbital, 5.3 g chloral hydrate, 2.7 g MgSO 4 .7 HO, 49.5 mL propylene glycol, 12.5 mL ethanol, and 58 mL distilled water, 0.3 mL/100 g body weight, intraperitoneally). A small incision was made in the dorsal neck region, and 1 minocycline pellet (28 day-release, 50 mg/kg per day minocycline pellet, Innovative Research, Novi, MI) or a placebo pellet (Innovative Research) was placed subcutaneously as previously described (14) . The skin was then sutured with coated Vicryl (Ethicon). Animals were killed 28 days after surgery while under Equithesin anesthesia by intra-aortic perfusion with cold PBS.
Morris Water Maze Task
The animals were required to find a submerged platform in a 100-cm-diameter pool of white nontoxic colored water using only distal and spatial clues available in the testing room. Throughout the study, all tests were carried out in the same room and setup. The center of the escape platform (4.5 cm diameter) was located 25 cm from the pool wall, in the northeast quadrant. Animals were tested in 15 trials during 5 consecutive days (3 trials per day with an intertrial time of 20 minutes) with the platform 1 cm below the water. At the end of the testing periods, all animals were given 3 trials in which the platform was raised 2 cm above the water to exclude visual or motor deficits as the cause of poor performance. The swim speeds, latencies, distances, and time spent in each quadrant were recorded using a video tracking system (HVS Image, Buckinghamshire, UK). For the probe test, mice were placed in the water maze with no platform for 3 trials of 60 seconds each with an intertrial interval of 20 minutes in a single day. The data are expressed as percentage of time spent in each quadrant TSEM, that is, the target quadrant being where the platform had been previously hidden.
Tissue Processing
Frozen tissues from middle frontal gyrus of nondemented (n = 7) and AD (n = 7) patients, hippocampal tissue from Fischer 344 rats, and cerebral cortex tissue from transgenic and nontransgenic mice were homogenized without thawing in 1 mL of homogenizing buffer (50 mmol/L Tris-HCl, 150 mmol/L NaCl, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate, 0.1% deoxycholic acid, 2 Kg/mL of aprotinin, 2 Kg/mL of leupeptin, 100 Kg/mL phenylmethanesulfonyl fluoride, pH 7.4). The homogenates were incubated for 15 minutes on ice and then centrifuged at 14,000 Â g for 30 minutes at 4-C, and protein content of the supernatants was determined using the DC protein assay, as described by the manufacturer (BioRad Laboratories, Hercules, CA). 
Antibodies and Reagents
Immunoprecipitation
To elute the protein with minimal antibody contamination, cross-linking of the antibodies (TrkA and NGF) to Sepharose A beads (Sigma-Aldrich, Canada) was performed following the Abcam online protocol. In brief, the Sepharose A beads were washed in 1 mL PBSYbovine serum albumin 1% wt/vol mix for 1 hour and rinsed in PBS twice. The supernatant was removed, and 400 KL of homogenizing buffer containing protease inhibitors was added. For each sample, 100 KL of beads were incubated with 300 Kg of total protein of brain homogenates overnight at 4-C under agitation. After washing the beads 3 times with homogenizing buffer at 4-C, loading buffer was added, and this was boiled at 95-C to 100-C for 5 minutes to denature the protein and separate it from the protein-A beads. The samples were then centrifuged, and the supernatant was loaded and resolved by sodium dodecyl sulfate<polyacrylamide gel electrophoresis.
Western Blot Analysis
Forty to 100 Kg of total protein of each sample was separated on 8% to 12% polyacrylamide resolving gels. Proteins were then transferred onto nitrocellulose membranes and blocked 1 to 2 hours at room temperature (RT) in TBS-T (Tris buffer, 10% Tween-20) with 5% (wt/vol) nonfat milk powder (Carnation). Incubations with primary antibodies were performed overnight at 4-C. After washing, membranes were incubated with horseradish peroxidase<conjugated secondary antibodies for 1 hour at RT. For detection, an enhanced chemiluminescence system (GE Healthcare Life Sciences, NJ) was used according to the manufacturer's instructions. The immunoreactive bands were quantified by densitometry of the films using MCID image analysis system. Values were normalized to A-III tubulin.
Gelatin Zymography
Sixty micrograms of each sample was resolved on 10% polyacrylamide gels containing 0.1% gelatin. After electrophoresis, the gel was incubated in zymogram renaturing buffer (Triton X-100, 25% [vol/vol] 
AA Oligomer Preparation
Amyloid-A oligomers were prepared as described by Demuro et al (15) . Briefly, soluble AA oligomers were prepared by dissolving 1.0 mg of peptide in 400 KL of hexafluoroisopropanol at RT. Then, 100 KL of the resulting seedless solution was added to 900 KL double-distilled water and centrifuged for 15 minutes at 14,000 Â g, and the supernatant fraction was transferred to a new tube and subjected to a gentle stream of N 2 for 5 to 10 minutes to evaporate the hexafluoroisopropanol. Finally, the samples were stirred at 500 rpm using a Teflon-coated microstir bar for 24 to 48 hours at 22-C. The final peptide concentration was 1 Kg/KL. The reverse control peptide (42-1) followed the same processing.
Dot Blot Analysis
Using a narrow-mouth pipette, 2 KL of fresh monomeric AA peptide and 2 KL of soluble AA oligomeric solution were spotted onto the nitrocellulose membrane. After drying, the membrane was soaked in 5% bovine serum albumin in TBS-T for 1 hour at RT to block nonspecific sites. The membrane was then incubated with different primary antibodies (A11 and 6E10 diluted 1:1000 in bovine serum albumin/TBS-T) for 1 hour at RT. The membrane was washed (3 Â 5 minutes) with TBS-T and incubated with the corresponding secondary antibody conjugated with horseradish peroxidase (1:10,000) for 30 minutes at RT. After washing (3 Â 5 minutes), the membrane was incubated with enhanced chemiluminescence reagent for 1 minute and exposed to x-ray film in the dark room.
Peroxynitrite-Modified NGF and Pro-NGF Preparations
Nerve growth factor (1 Kg) or recombinant pro-NGF (1 Kg) was treated with peroxynitrite in 50 mmol/L sodium phosphate buffer and 20 mmol/L sodium bicarbonate, pH 7.4, following the protocol described by Pehar et al (16) . At the time of the experiment, peroxynitrite concentration (by absorbance at 302 nm) was ? = 1,690 M j1 cm-1 . Fresh stock solutions were prepared in 0.01 mol/L NaOH, and the reaction was performed at 37-C. Peroxynitrite was added to the top of the tube (containing NGF or pro-NGF) 5 times and mixed by vortexing for 3 seconds to reach the final peroxynitrite concentration of 1 mmol/L. The same procedures were applied for decomposed peroxynitrite (reverse-order addition) diluted in 0.001 mol/L NaOH.
Statistical Analysis
Statistical significance between pixel values for control and AD groups was calculated using the t-test; bars represent the mean intensities TSEM for each group. Behavioral data were subjected to univariate and multivariate analysis of variance. For repeated measures, the Huynh-Feldt p value is reported. Between-group comparisons were made using Tukey test. All probabilities were 2-tailed; a level of 5% was considered significant.
RESULTS
Altered NGF Maturation and Cortical Pro-NGF Accumulation in AD Brain
In the AD samples, there were greater levels of pro-NGF (32 kd band, p G 0.01; Fig. 2A ), decreased levels of plasminogen (p G 0.05; Fig. 2B ) and tPA (p G 0.05), and a correspondently significant decrease in the formation of plasmin (p G 0.001; Figs. 2B, C; Table) compared with controls; plasmin ultimately converts pro-NGF into mature NGF (11, 17) . These results indicate that there is a marked deficit in the cascade responsible for NGF maturation in AD. This failure in pro-NGF conversion would explain the progressive accumulation of pro-NGF in AD cerebral cortex in the presence of normal NGF mRNA levels (5, 6).
Increased NGF Degradation Activity in AD
Greater levels of MMP-9 have been identified in AD than in age-matched control samples of hippocampal tissue (18) and plasma (19) . We confirmed increased levels and activity of MMP-9 in cortical human AD brain tissue as assessed by Western blot analysis (p G 0.001; Fig. 2D ; Table) and gelatin zymography (p G 0.001; Fig. 2D ), respectively. Moreover, no significant changes in the tissue inhibitor of MMP-9, tissue inhibitor of metalloproteinase 1, were observed in AD cortical tissue compared with age-matched controls (p 9 0.05; Fig. 2E ).
Matrix metalloproteinase 9 is released in an activitydependent manner as a propeptide (pro-MMP-9) that can be then activated by plasmin (11), but we found increased pro-MMP-9 and MMP-9 levels in cortical AD samples, strongly suggesting an alternative mechanism for MMP-9 activation because the tPA/plasminogen/plasmin system is downregulated in AD. Because S-nitrosylation of pro-MMP-9 by NO has been described as an alternative mechanism for activation of MMP-9 in response to oxidative stresses (20) and AA directly induces the expression of MMP-9 (21), we investigated whether NO production participates in this NGF metabolic dysregulation in AD brains.
Microglia Activation and NO Production in AD
Activation of microglia by aggregated AA is a central feature in the chronic inflammatory pathology in AD (22) anda direct indicator of an ongoing chronic inflammatory process. Nitric oxide is synthesized by a family of enzymes named NOS, including iNOS, endothelial NOS, and neuronal NOS. Inducible NOS is found in activated microglia, whereas NO production (23) and neuronal expression of iNOS are also found in AD brains (24, 25) . We investigated the levels of activated microglia and iNOS expression in cortical AD tissue and compared these with age-matched controls. CD40 expression is a well-established marker of microglial activation, which is upregulated in the presence of AA peptides (26, 27) . CD40 is also upregulated by activated microglia in AD brains (28, 29) . Consistent with these previous reports, we found increased levels of both CD40 (p G 0.001; see Supplemental in AD brains. The increased brain content of NO would facilitate the observed hyperactivity of MMP-9 in AD, thereby diminishing the availability of biologically active NGF. Based on the above observations, we performed further studies to determine whether microglial activation and increased NO production could be triggered by AA-oligomers in vivo.
In Vivo Effects of Injected Soluble AA Oligomers on Pro-NGF Levels and MMP-9 Activity
Brain levels of soluble AA in AD show a stronger correlation with cognitive impairments than plaque density (30Y32). Consequently, our next step was to investigate whether the altered expression of pro-NGF, MMP-9, CD40, FIGURE 3. In vivo effects of soluble amyloid A (AA) oligomers in the nerve growth factor (NGF) maturation/degradation cascade. (A) Before hippocampal injections, the formation of soluble AA oligomers were confirmed by dot blot analysis using the A11 antibody that recognizes the presence of oligomers and the 6E10 antibody that recognizes monomers and oligomeric forms of AA. (B) Seventy-two hours after AA oligomers (Oligo) or reverse peptide (42-1) were injected into the hippocampus, levels of precursor form of NGF (pro-NGF) were determined by Western blot and matrix metalloproteinase 9 (MMP-9) activity was analyzed by gelatin zymography. Note the upregulation of pro-NGF levels and of MMP-9 activity in hippocampi receiving AA oligomers. and iNOS observed in AD brains could be triggered by neurotoxic AA oligomers (33) . We administered a single injection of soluble AA oligomers (ipsilateral, 1 Kg/3 KL) versus the reverse peptide 42-1 as control (contralateral, 1 Kg/3KL) in the rat hippocampus for 72 hours. Soluble AA oligomers were prepared as previously described (15) , and the AA oligomerization was confirmed by dot blot analysis, applying the oligomeric peptide-specific A11 antibody (34) and 6E10 antibody using the monomeric peptide form as control (Fig. 3A) . In AA oligomer<injected hippocampi, we found increased levels of pro-NGF (p G 0.01) and of MMP-9 activity (p G 0.001) compared with the reverse peptideinjected contralateral hippocampi (Figs. 3B, C) . Moreover, tPA levels were markedly decreased in the AA oligomers< injected side compared with the reverse peptide<injected side (data not shown).
Minocycline Prevented the AA Oligomer<Induced Alterations in the NGF Maturation/Degradation Cascade and in Microglial Activation
These observations led us to speculate that targeting microglial activation to prevent iNOS expression and NO production in AD could correct the increased pro-NGF levels and/or the MMP-9 hyperactivation, along with preventing microglial activation. To test this, rats infused with soluble AA oligomers were treated with minocycline, a tetracycline derivative that has been shown to attenuate microglial activation by decreasing the production of proinflammatory molecules (35) , lowering iNOS expression (36, 37) and inhibiting MMP-9 (12). Minocycline was administered 24 hours before soluble AA oligomers were injected and daily afterward for 72 hours; animals were then killed, and hippocampal tissue was processed for neurochemical analysis. Minocycline-treated animals infused with AA oligomers were significantly protected from the AA-induced upregulation of pro-NGF (p G 0.01) and of MMP-9 (p G 0.001) as well as the elevation of microglial CD40 (p G 0.001) and of iNOS (p G 0.05) expression compared with AA oligomer<infused rats not treated with minocycline (Figs. 3D, E) . No statistically significant differences were found between minocycline-treated rats injected with soluble AA oligomers and rats injected only with 42-1 reverse control peptide.
Peroxynitrite-Mediated Nitrotyrosine Formation in Pro-NGF and NGF
We next investigated whether increased NO production could impact the degree of pro-NGFYperoxynitration or on NGF activity. Nitrotyrosine immunoreactivity has been shown to be 5-to 8-fold higher in areas of neurodegeneration in AD brain than in cognitively normal subjects (25, 38, 39) . In agreement with these findings, we observed a clear increment in the content and number of nitrotyrosine-immunoreactive bands in AD brain samples compared with age-matched controls (Fig. 4A) .
We further investigated whether the increased cortical pro-NGF seen in AD also contains nitrotyrosine residues. Material immunoprecipitated with anti-NGF and resolved by Western blot was found to contain a high-molecular band (32kd) corresponding to pro-NGF (Fig. 4B) , the predominant form of NGF in the human (7) and rodent brain (11) . Equally loaded immunoprecipitated material resolved by Western blot was probed with an antibody against nitrotyrosine, demonstrating the presence of nitrotyrosine-positive bands in AD brain samples and almost undetectable levels of nitrated pro-NGF in age-matched controls (Fig. 4C) . These results indicated that there is a clear accumulation of peroxynitritemodified pro-NGF in cortical tissue of AD brain.
As shown in Figure 3D , a single injection of soluble AA oligomers into the rat hippocampus increased levels of iNOS after 72 hours. To test the possibility that under such conditions peroxynitration of protein does occur, the brain homogenates were further resolved by Western blot analysis using the nitrotyrosine antibody. As expected, additional nitrotyrosine-positive bands appeared in the samples injected with AA oligomers compared with the control samples injected with 42-1 reverse peptide. Moreover, this peroxynitrite-mediated oxidative damage could be prevented by treatment with minocycline (Fig. 4D) . To investigate whether soluble AA oligomers are specifically able to induce the nitration of tyrosine residues in pro-NGF/NGF molecules, these proteins were immunoprecipitated with NGF antibodies. This revealed an accumulation of nitrated pro-NGF in the samples injected with soluble AA oligomers; this was also prevented by minocycline treatment (Fig. 4E) .
To understand whether the pro-NGF accumulation observed in AD cortical tissue could be induced by the peroxynitrite-mediated oxidation of pro-NGF, recombinant purified recombinant pro-NGF (32 kd) and mature NGF (14 kd) were treated with peroxynitrite (ONOO Y , 1 mmol/L) as previously described (16) . The reaction products were resolved by Western blot analysis using anti-NGF (Fig. 4F ) and antinitrotyrosine antibodies (Fig. 4G) . Mature NGF (Lane 1) and pro-NGF (Lane 4) were also treated with decomposed peroxynitrite (1 mmol/L, Lines 2 and 5, respectively) as controls. No differences were observed after decomposed peroxynitrite treatment compared with untreated mature NGF and recombinant pro-NGF. After peroxynitrite treatment, however, nitrotyrosine-positive bands were observed for both NGF and pro-NGF (Lanes 3 and 6, respectively). In addition, we tested whether plasmin was capable of maturing peroxynitrite-modified pro-NGF. In Figure 4F Lane 7, 2 NGF-positive bands corresponding to pro-NGF and mature NGF can be seen; these indicate that plasmin was able to convert peroxynitrite-modified pro-NGF into nitrotyrosine-containing mature NGF. After plasmin treatment, this reactive product was resolved using a nitrotyrosine antibody; a 14-kd band corresponding to mature NGF was observed (Fig. 4G, Line 7) . This result indicates that peroxynitrite-modified pro-NGF is converted by plasmin into nitrated mature NGF.
Altered Capacity of Peroxynitrite-Modified NGF to Induce Phosphorylation of TrkA In Vivo
To investigate whether the lack of trophic support of oxidized NGF displayed in vitro with cultured dorsal root ganglion neurons (see Supplemental Fig. 2 , Supplemental Digital Content 2, http://links.lww.com/A1400) is also seen in vivo, we injected native NGF and peroxynitrite-modified NGF unilaterally into the rat hippocampus. At 2 hours after the injections, we determined the levels of TrkA autophosphorylation in the hippocampus. After immunoprecipitation using an anti-TrkA antibody, Western blots of phosphorylated TrkA and total TrkA (Fig. 4H) revealed a significant reduction in the level of TrkA phosphorylation (p G 0.001) on the side injected with peroxynitrite-modified NGF compared with the side injected with native NGF. These results indicate that peroxynitrite modifies NGF activity, resulting in a reduced ability to induce TrkA autophosphorylation and, therefore, disrupting the first steps in the NGF signaling cascade.
Minocycline Treatment of the McGill-Thy1-APP Transgenic Mouse Model Prevented Alterations on the NGF Maturation/Degradation Cascade and Ameliorated Behavioral Deficits
We further investigated whether the modifications in content and nitration of pro-NGF/NGF observed in AD brain samples and in rats infused with soluble AA oligomers were also present in the McGill-Thy1-APP transgenic mouse model (see Supplemental Fig. 3A , Supplemental Digital Content 3, http://links.lww.com/A1401). The observed behavioral impairment at 3 months of age in these mice (see Supplemental Fig. 3B , Supplemental Digital Content 3, http://links.lww.com/A1401) was coincident with increased cortical pro-NGF (p G 0.05) and iNOS (p G 0.05) content and altered MMP-9 activity (p G 0.05) (see Supplemental Fig. 3B , Supplemental Digital Content 3, http://links.lww.com/A1401). We administered minocycline to these mice daily for 28 days, starting 1 month before the appearance of cognitive deficits and dysregulation of the NGF processing pathway. Transgenic mice (n = 8) received a dose of minocycline in pellet formulation previously shown to be neuroprotective (50 mg/kg per day) (14) , whereas a transgenic mouse control group (n = 8) received placebo pellets. As controls, we also included 2 groups of littermate nontransgenic mice given placebo (n = 8) or minocycline (n = 7) pellets. At the end of the treatment, the animals were tested for their ability to learn the Morris water maze task, as previously described (40) . There were no differences in performance between placebo and minocycline nontransgenic control groups in the acquisition of the Morris water maze task (Fig. 5A) . On the other hand, the performance of the transgenic placebo-treated group differed from those of the nontransgenic placebo-treated littermates (p G 0.0001, F 4,60 = 36.70) and the minocycline-treated transgenic group (p G 0.0001, F 4,60 = 13.40). There were no statistically significant differences in performance between the nontransgenic littermates and the minocycline-treated transgenic group (p 9 0.02, F = 3.09) (Fig. 5A) . The quadrant analysis performed during the probe test 24 hours after the end of the acquisition phase (Fig. 5B) revealed that placebo-treated transgenic mice spent significantly less time (as a percentage) in the quadrant where the platform was located as compared with the other treated groups (p G 0.001).
Biochemical analysis of inflammatory markers and pro-NGF in minocycline-treated transgenic animals showed normalization of cortical pro-NGF and iNOS levels as well as of MMP-9 activity (Fig. 5C ). As shown in Figure 5D , transgenic mice receiving placebo treatment displayed increased pro-NGF levels (p G 0.01) analogous to that observed in AD, whereas the level of pro-NGF in minocycline-treated mice statistically did not differ from the levels found in nontransgenic littermates (p 9 0.05). When the cortical NGF from minocycline-treated mice was immunoprecipitated and blotted with antinitrotyrosine antibody, the content of peroxynitritemodified pro-NGF was found to be markedly reduced (Fig. 5C ). Furthermore, minocycline treatment also normalized the MMP-9 activity (p G 0.01) and reduced the altered levels of iNOS (p G 0.05) observed in transgenic mice treated with placebo (Figs. 5E, F, respectively).
DISCUSSION
We found a marked alteration in the level of the protease cascade responsible for NGF maturation in human AD cortical tissue. Diminished plasmin formation in AD brain would reduce the NGF maturation process, resulting in the accumulation of pro-NGF. In addition, we found increased levels of MMP-9 and of its proteolytic activity in AD cortical tissue. This protease can rapidly degrade mature NGF, but it does not convert pro-NGF into mature NGF (11) . The combination of diminished conversion to mature biologically active NGF along with the increased levels and activity of the NGF-degrading . The final reaction products were separated by sodium dodecyl sulfate< polyacrylamide gel electrophoresis and blotted with anti-NGF antibody. (G) The same reaction products were immunoblotted with antinitrotyrosine antibody revealing the presence on peroxynitrite-modified NGF (Lane 3), peroxynitrite-modified pro-NGF (Lane 6), and peroxynitrite-modified mature NGF derived from peroxynitrite-modified pro-NGF and converted (matured) by the action of plasmin (Lane 7). (H) Reduced capacity of peroxynitrite-modified NGF to induce TrkA phosphorylation in vivo. A total of 150 ng of native NGF or peroxynitrite-modified NGF were injected into the rat hippocampus, and 2 hours later, the animals where killed, and the tissue was subjected to immunoprecipitation with TrkA antibody and separated by Western blot. When compared with the side injected with native NGF, peroxynitrite-modified NGF displayed a significant reduction in its capacity to induce TrkA phosphorylation (n = 5; p G 0.001).
protease MMP-9 creates a situation of double jeopardy for the trophic support of BFCNs in AD brain. It is, thus, plausible that alterations in the balance of NGF maturation and degradation may be the cause of abnormally elevated pro-NGF in AD and that this could provoke or contribute to the remarkable vulnerability of the NGF-dependent forebrain cholinergic Current evidence supports the view that soluble A amyloid peptides induce impairments of memory formation (41Y43), a mechanism that probably involves the basal forebrain cholinergic system (44, 45) . We investigated whether the observed impaired processing of pro-NGF and the increased degradation of NGF was directly linked to the occurrence of neurotoxic AA oligomers in the brain. Our observations support the notion that the presence of AA oligomers in the brain is sufficient to induce the elevation of pro-NGF levels and the synthesis and activation of MMP-9.
There is increasing evidence indicating that oxidative damage to proteins and other macromolecules is a salient feature of AD pathology (25, 39, 46Y48) . Microglial cells are normally in a resting state, but in AD, they gradually become activated with simultaneous production of superoxide and NO (23, 39) . In vitro studies have shown that activated microglia become neurotoxic through generation of peroxynitrite, a powerful oxidant molecule formed by the reaction of superoxide with NO (49Y51). Peroxynitrite is a potent oxidant and nitrating agent involved in the oxidation and nitration of tyrosine residues in proteins (47, 52) . Our observations in AD brain, in studies involving delivery of soluble AA oligomers into rat hippocampus and in transgenic mice, reinforce the concept that microglial activation leading to iNOS production would result in peroxynitrite-mediated nitration of key metabolic proteins, including neurotrophins. Moreover, there is now considerable evidence that inflammatory stimuli induce the expression of iNOS mRNA, protein, and enzymatic activity in neuronal populations in AD (53) . However, regardless of its origin (glial or neuronal), NO is a soluble diffusible gas that may act on neighboring cells by forming peroxynitrite and thus nitrating key proteins. This situation might signal the involvement of an added factor in the pathogenesis of neurodegeneration in AD because it has been shown that peroxynitrite converts NGF into proapoptotic factor in motor neurons (16) . Other investigators have, however, proposed that motor neuron cell death is mediated by peroxynitrite-induced release of pro-NGF instead of NGF (54) .
Cortical accumulation of pro-NGF might favor atrophy or cell death of NGF-dependent neurons as it binds with high affinity to p75 NTR but does not bind to the TrkA receptor (55). Because we found high levels of peroxynitrite-modified pro-NGF in AD brain that could be partially converted to peroxynitrited NGF, we investigated whether this molecular form can sustain biologic responses in TrkA-expressing neurons. We observed that nitrated NGF loses biologic activity, as reflected by the poor survival of newly cultured dorsal root ganglion neurons or a diminished neuronal phenotype of mature and fully differentiated dorsal root ganglion cultures. Such molecular modifications would have a further negative impact in the trophic support of NGF-dependent neurons in the context of AD. Our in vivo experiments of injecting peroxynitrated NGF into the hippocampus would further reinforce this concept. The present findings add a new perspective to the poorly understood vulnerability of BFCNs in AD. The well-noted reduction of TrkA proteins in AD (10) would be in line with the present findings of perturbed NGF maturation and increased degradation and peroxynitration of NGF. It would also concur with the well-established notion that TrkA gene expression is induced by biologically active mature NGF (56Y58).
In summary, our results suggest that AA-induced AD pathology involves a profound alteration in the maturation, degradation, and degree of peroxynitration of NGF. This scenario would result in a drastic reduction of the biologic actions of NGF needed for the phenotypic maintenance of the NGF-dependent BFCNs as a consequence of the AA burden in AD. Our findings also suggest that some of the alterations in NGF metabolism are generated by AA-induced microglial activation. Based on the present results, Figure 6 summarizes the proposed alterations of the NGF metabolism in AD. FIGURE 6 . Schematic representation of the disruption in the nerve growth factor (NGF) maturation/degradation pathway. Amyloid A<induced microglial activation would generate inducible nitric oxide synthetase (iNOS) expression, NO production, peroxynitrite formation, increased matrix metalloproteinase 9 (MMP-9) activity, thus altering NGF maturation/degradation pathway and NGF peroxynitration, ultimately leading to the trophic disconnection of basal forebrain cholinergic neurons. MMP-9, matrix metalloproteinase 9; tPA, tissue plasminogen activator.
